AgomAb Therapeutics (NASDAQ:AGMB) CEO Tim Jasper Knotnerus Acquires 5,000 Shares of Stock

AgomAb Therapeutics NV (NASDAQ:AGMB) CEO Tim Jasper Knotnerus purchased 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 6th. The shares were purchased at an average cost of $8.70 per share, for a total transaction of $43,500.00. Following the completion of the transaction, the chief executive officer owned 21,823 shares in the company, valued at approximately $189,860.10. This represents a 29.72% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Tim Jasper Knotnerus also recently made the following trade(s):

• On Monday, October 5th, Tim Jasper Knotnerus bought 6,000 shares of AgomAb Therapeutics stock. The stock was bought at an average price of $8.48 per share, with a total value of $50,880.00.

AgomAb Therapeutics Stock Performance

NASDAQ:AGMB opened at $8.84 on Wednesday. The business has a 50 day simple moving average of $12.82 and a 200 day simple moving average of $12.00. AgomAb Therapeutics NV has a 12-month low of $7.97 and a 12-month high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last issued its earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. On average, equities research analysts predict that AgomAb Therapeutics NV will post -1.76 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on AGMB shares. Piper Sandler started coverage on shares of AgomAb Therapeutics in a research report on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price objective on the stock. Cantor Fitzgerald initiated coverage on shares of AgomAb Therapeutics in a research note on Wednesday, August 19th. They issued an “overweight” rating on the stock. HC Wainwright reaffirmed a “buy” rating on shares of AgomAb Therapeutics in a report on Wednesday, September 16th. Wall Street Zen downgraded AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, September 27th. Finally, B. Riley Financial started coverage on AgomAb Therapeutics in a report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price objective for the company. Seven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $37.50.

About AgomAb Therapeutics

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab’s lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn’s disease.